Kamada
Yahoo Finance • last year
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Ye... Full story
Yahoo Finance • last year
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions... Full story
Yahoo Finance • last year
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
Kamada Ltd. The Extended Agreement Term is Until March 2026 The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB toKedrion in 2022 and Anticipates a Significant Increase in 2023 REHOVOT, Israel, and HOBOKEN, N... Full story
Yahoo Finance • 2 years ago
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Kamada Ltd. REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious co... Full story
Yahoo Finance • 2 years ago
Kamada Announces Planned Transition of Chief Financial Officer
REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced t... Full story
Yahoo Finance • 2 years ago
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it... Full story
Yahoo Finance • 2 years ago
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to DateIndependent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time Since Study InitiationBased on Encouragin... Full story
Yahoo Finance • 2 years ago
Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed
REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Em... Full story
Yahoo Finance • 3 years ago
Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022
Kamada Ltd. REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will rele... Full story
